The case involved a claim that selling faulty infusion devices to the government was a violation of the FCA, based on an implied false certification theory of liability under the statute. The official ruling of the court was a “cognizable implied false certification claim under the FCA” was not established by the prosecution. However, a concurring opinion from the court advocated “restoring Congress’s statutory distinction between falsity and fraud, and using traditional, common-sense understandings of those terms, in combination with ‘strict enforcement of the Act’s materiality and scienter requirements,'” according to the report.
The decision follows similar rulings from the Sixth Circuit and a Massachusetts district court, according to the report.
More Articles on Court Rulings:
Akron Children’s Goes to Court to Ensure Chemo for Amish Girl
Phoebe Putney Won’t Have to Sell Palmyra Hospital in FTC Settlement
Judge Orders SUNY to Partially Restore LICH Services
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.